Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
7 hedge funds and large institutions have $78.2K invested in Kiromic BioPharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
2.34% less ownership
Funds ownership: 4.41% → 2.07% (-2.3%)
42% less funds holding
Funds holding: 12 → 7 (-5)
46% less capital invested
Capital invested by funds: $146K → $78.2K (-$67.3K)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$87K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.42K |
| 3 |
BlackRock
New York
|
+$4.28K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$11 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$99.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$7K |
| 3 |
VF
Virtu Financial
New York
|
-$6K |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.06K |
| 5 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
-$1.81K |
KRBP Hedge Fund Activity: Q1 2023 in Review
7 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q1 2023, worth a combined $78.2K — down 46% from $146K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of KRBP and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $87K. The largest seller was Sabby Management, exiting entirely with an estimated $99.4K sold.
- 7 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q1 2023, down from 12 in Q4 2022.
- Funds reported $78.2K of Kiromic BioPharma, Inc. Common Stock stock for Q1 2023, down 46% quarter-over-quarter.
- 2 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q1 2023 and 6 closed out, a net change of -4 holders.
- The largest Kiromic BioPharma, Inc. Common Stock buyer in Q1 2023 was Susquehanna International Group, an estimated $87K added.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q1 2023 was Sabby Management, an estimated $99.4K sold.
Based on aggregated 13F filings for Q1 2023.